{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:33:44Z","timestamp":1793212424395,"version":"4.5.0"},"reference-count":22,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002066","name":"GSK","doi-asserted-by":"publisher","award":["204989"],"award-info":[{"award-number":["204989"]}],"id":[{"id":"10.13039\/501100002066","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000016","name":"US Department of Health and Human Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000016","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100021704","name":"Administration for Strategic Preparedness and Response","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100021704","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["HHSO100201300011C"],"award-info":[{"award-number":["HHSO100201300011C"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012399","name":"Biomedical Advanced Research and Development Authority","doi-asserted-by":"publisher","award":["212390"],"award-info":[{"award-number":["212390"]}],"id":[{"id":"10.13039\/100012399","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,10,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Two phase 3 trials (EAGLE-2 [NCT04020341]\/EAGLE-3 [NCT04187144]) demonstrated the efficacy of gepotidacin, a novel, first-in-class triazaacenaphthylene antibacterial, versus nitrofurantoin for the treatment of uncomplicated urinary tract infections (uUTIs). Using pooled data, we assessed gepotidacin efficacy across clinically important subgroups, including participants with nitrofurantoin not-susceptible (NTF-NS; ie, resistant, intermediate or no interpretation) uropathogens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Female participants aged \u226512 years with uUTI received gepotidacin (1500 mg) or nitrofurantoin (100 mg), both twice daily for 5 days. Therapeutic success at test-of-cure (day 10\u201313) was defined as combined complete symptom resolution (clinical success) and reduction of baseline qualifying uropathogens from \u2265105 to &amp;lt;103 CFU\/mL (microbiological success), without other systemic antibacterials. Response rates at test-of-cure were descriptively summarized in the pooled microbiological intent-to-treat (micro-ITT) nitrofurantoin-susceptible (NTF-S) and NTF-NS populations, and across prespecified subgroups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In the micro-ITT NTF-S population, treatment differences (in favor of gepotidacin) [95% confidence interval] for therapeutic, clinical and microbiological success were: 9.6% [4.1, 15.2], 2.8% [\u22122.4, 8.1], and 10.4% [5.2, 15.6]. Corresponding treatment differences were higher in the micro-ITT NTF-NS population: 20.8% [9.2, 32.4], 10.3% [\u22121.4, 22.1], 20.7% [9.2, 32.3]. In both of these populations, gepotidacin success rates (all endpoints) were similar to or higher than nitrofurantoin across prespecified subgroups at higher risk for antimicrobial resistant uropathogens (age &amp;gt;50 years, history of recurrent uUTI, diabetes, mild renal impairment, extended-spectrum \u03b2-lactamase-producing or fluoroquinolone-resistant uropathogens).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Gepotidacin demonstrated efficacy with generally higher therapeutic success rates versus nitrofurantoin in participants with NTF-S and NTF-NS uropathogens, and across a range of key subgroups.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/cid\/ciag408","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:29:26Z","timestamp":1783470566000},"page":"e733-e742","source":"Crossref","is-referenced-by-count":0,"title":["Subgroup Analysis of Pooled Phase 3 Efficacy Data From Two Randomized Trials of Gepotidacin Versus Nitrofurantoin in Uncomplicated Urinary Tract Infections (EAGLE-2 and EAGLE-3) Including Participants With Uropathogens Not-Susceptible to Nitrofurantoin"],"prefix":"10.1093","volume":"83","author":[{"given":"Amanda","family":"Sheets","sequence":"first","affiliation":[{"name":"Vaccine & ID Research Unit, GSK , Collegeville, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0063-0614","authenticated-orcid":false,"given":"Jeremy","family":"Dennison","sequence":"additional","affiliation":[{"name":"Respiratory, Immunology, and Inflammation Research Unit, GSK , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4744-8067","authenticated-orcid":false,"given":"Jennifer H","family":"Han","sequence":"additional","affiliation":[{"name":"Vaccine & ID Research Unit, GSK , Collegeville, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Watts","sequence":"additional","affiliation":[{"name":"Respiratory, Immunology, and Inflammation Research Unit, GSK , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6387-319X","authenticated-orcid":false,"given":"Caroline","family":"Perry","sequence":"additional","affiliation":[{"name":"Vaccine & ID Research Unit, GSK , Collegeville, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4211-8261","authenticated-orcid":false,"given":"Nicole E","family":"Scangarella-Oman","sequence":"additional","affiliation":[{"name":"Vaccine & ID Research Unit, GSK , Collegeville, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Butler","sequence":"additional","affiliation":[{"name":"Vaccine & ID Research Unit, GSK , Collegeville, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7989-5465","authenticated-orcid":false,"given":"John","family":"Breton","sequence":"additional","affiliation":[{"name":"Vaccine & ID Research Unit, GSK , Collegeville, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5810-6543","authenticated-orcid":false,"given":"Thomas M","family":"Hooton","sequence":"additional","affiliation":[{"name":"Infectious Disease Medicine and Internal Medicine, University of Miami , Miami, Florida ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Millns","sequence":"additional","affiliation":[{"name":"Vaccines and Infectious Disease, GSK , Stevenage ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Helgeson","sequence":"additional","affiliation":[{"name":"Vaccine & ID Research Unit, GSK , Collegeville, Pennsylvania ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salim","family":"Janmohamed","sequence":"additional","affiliation":[{"name":"Respiratory, Immunology, and Inflammation Research Unit, GSK , London ,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"2026102813491150500_ciag408-B1","doi-asserted-by":"crossref","first-page":"1756287219832172","DOI":"10.1177\/1756287219832172","article-title":"An introduction to the epidemiology and burden of urinary tract infections","volume":"11","author":"Medina","year":"2019","journal-title":"Ther Adv Urol"},{"key":"2026102813491150500_ciag408-B2","first-page":"e02359","article-title":"Impact of empirical antibiotic therapy on outcomes of outpatient urinary tract infection due to nonsusceptible Enterobacterales","volume":"10","author":"Dunne","year":"2022","journal-title":"Am Soc Microbiol"},{"key":"2026102813491150500_ciag408-B3","doi-asserted-by":"crossref","first-page":"e0256464","DOI":"10.1371\/journal.pone.0256464","article-title":"Risk factors for treatment failure in women with uncomplicated lower urinary tract infection","volume":"16","author":"Martischang","year":"2021","journal-title":"PLoS One"},{"key":"2026102813491150500_ciag408-B4","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/nature09197","article-title":"Type IIA topoisomerase inhibition by a new class of antibacterial agents","volume":"466","author":"Bax","year":"2010","journal-title":"Nature"},{"key":"2026102813491150500_ciag408-B5","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1021\/acsinfecdis.8b00315","article-title":"Mechanistic and structural basis for the actions of the antibacterial gepotidacin against","volume":"5","author":"Gibson","year":"2019","journal-title":"ACS Infect Dis"},{"key":"2026102813491150500_ciag408-B6","first-page":"1918","article-title":"In vitro activity of gepotidacin, a novel triazaacenaphthylene bacterial topoisomerase inhibitor, against a broad spectrum of bacterial pathogens","volume":"60","author":"Biedenbach","year":"2016","journal-title":"Am Soc Microbiol"},{"key":"2026102813491150500_ciag408-B7","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1021\/acsinfecdis.3c00346","article-title":"Interactions between gepotidacin and Escherichia coli gyrase and topoisomerase IV: genetic and biochemical evidence for well-balanced dual-targeting","volume":"10","author":"Oviatt","year":"2024","journal-title":"ACS Infect Dis"},{"key":"2026102813491150500_ciag408-B8","volume-title":"Blujepa (gepotidacin) approved by US FDA for treatment of uncomplicated urinary tract infections (uUTIs) in female adults and paediatric patients 12 years of age and older","author":"GSK","year":"2025"},{"key":"2026102813491150500_ciag408-B9","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(23)02196-7","article-title":"Oral gepotidacin versus nitrofurantoin in patients with uncomplicated urinary tract infection (EAGLE-2 and EAGLE-3): two randomised, controlled, double-blind, double-dummy, phase 3, non-inferiority trials","volume":"403","author":"Wagenlehner","year":"2024","journal-title":"Lancet"},{"key":"2026102813491150500_ciag408-B10","doi-asserted-by":"crossref","first-page":"2297","DOI":"10.1007\/s40121-022-00706-9","article-title":"Design of two phase III, randomized, multicenter studies comparing gepotidacin with nitrofurantoin for the treatment of uncomplicated urinary tract infection in female participants","volume":"11","author":"Perry","year":"2022","journal-title":"Infect Dis Ther"},{"key":"2026102813491150500_ciag408-B11","author":"U.S. Food and Drug Administration"},{"key":"2026102813491150500_ciag408-B12","author":"European Medicines Agency"},{"key":"2026102813491150500_ciag408-B13","volume-title":"M100\u2013performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2022","edition":"32 ed"},{"key":"2026102813491150500_ciag408-B14","volume-title":"In vitro activity of gepotidacin against baseline uropathogenic phenotypes and genotypes recovered from EAGLE-2\/EAGLE-3 clinical trials for uncomplicated urinary tract infections","author":"Scangarella-Oman","year":"2024"},{"key":"2026102813491150500_ciag408-B15","doi-asserted-by":"crossref","first-page":"ofac623","DOI":"10.1093\/ofid\/ofac623","article-title":"Risk factors associated with antimicrobial resistance and adverse short-term health outcomes among adult and adolescent female outpatients with uncomplicated urinary tract infection","volume":"9","author":"Trautner","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"2026102813491150500_ciag408-B16","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1186\/s12879-019-3804-y","article-title":"The role of extended-spectrum cephalosporin-resistance in recurrent community-onset Enterobacteriaceae urinary tract infections: a retrospective cohort study","volume":"19","author":"Anesi","year":"2019","journal-title":"BMC Infect Dis"},{"key":"2026102813491150500_ciag408-B17","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1017\/ice.2018.254","article-title":"Poor clinical outcomes associated with community-onset urinary tract infections due to extended-spectrum cephalosporin-resistant Enterobacteriaceae","volume":"39","author":"Anesi","year":"2018","journal-title":"Infect Control Hosp Epidemiol"},{"key":"2026102813491150500_ciag408-B18","doi-asserted-by":"crossref","first-page":"927","DOI":"10.15537\/smj.2022.43.8.20220238","article-title":"The prevalence of multiple drug resistant urinary tract infections: a single-centered, observational retrospective study in King Abdulaziz specialized hospital, Taif, Saudi Arabia","volume":"43","author":"Alhomayani","year":"2022","journal-title":"Saudi Med J"},{"key":"2026102813491150500_ciag408-B19","author":"U.S. Food and Drug Administration"},{"key":"2026102813491150500_ciag408-B20","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/cpdd.807","article-title":"Pharmacokinetics of gepotidacin in renal impairment","volume":"9","author":"Hossain","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"key":"2026102813491150500_ciag408-B21","doi-asserted-by":"crossref","first-page":"ofad500.2441","DOI":"10.1093\/ofid\/ofad500.2441","article-title":"2831. Efficacy and safety of gepotidacin for uncomplicated urinary tract infection: pooled subgroup analyses of the EAGLE-2 and EAGLE-3 randomized phase 3 trials","volume":"10","author":"Hooton","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026102813491150500_ciag408-B22","doi-asserted-by":"crossref","first-page":"ofae631.164","DOI":"10.1093\/ofid\/ofae631.164","article-title":"512. Efficacy of gepotidacin versus nitrofurantoin in a nitrofurantoin not susceptible population: a pooled analysis of the EAGLE-2 and EAGLE-3 randomized controlled trials in uncomplicated urinary tract infection","volume":"12","author":"Dennison","year":"2025","journal-title":"Open Forum Infect Dis"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciag408\/68710791\/ciag408.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/83\/4\/e733\/68710791\/ciag408.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/83\/4\/e733\/68710791\/ciag408.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:49:23Z","timestamp":1793209763000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/83\/4\/e733\/8726526"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":22,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,7,8]]},"published-print":{"date-parts":[[2026,10,28]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciag408","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,15]]},"published":{"date-parts":[[2026,7,8]]}}}